MedPath

Dronabinol

Generic Name
Dronabinol
Brand Names
Marinol, Sativex, Syndros
Drug Type
Small Molecule
Chemical Formula
C21H30O2
CAS Number
1972-08-3
Unique Ingredient Identifier
7J8897W37S
Background

Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments .

Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are found throughout the body . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms like Dronabinol or Nabilone), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers.

From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . The endocannabinoid system is widely distributed throughout the central and peripheral nervous system (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others . CB1 receptors are found in both the central and peripheral nervous system, and are most abundant in the hippocampus and amygdala, which are the areas of the brain responsible for short-term memory storage and emotional regulation. CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function .

Indication

Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Associated Conditions
Anorexia, Chemotherapy-Induced Nausea and Vomiting

Cannabis (THC vs. CBD) in Multiple Sclerosis

Phase 2
Not yet recruiting
Conditions
Multiple Sclerosis
Interventions
First Posted Date
2024-02-15
Last Posted Date
2024-02-15
Lead Sponsor
University of Calgary
Target Recruit Count
30
Registration Number
NCT06261489

High Confusion: Cannabis & Driving

Early Phase 1
Recruiting
Conditions
Impairment, Psychomotor
Impairment, Cognitive
Impairment of Attention
Interventions
First Posted Date
2024-02-01
Last Posted Date
2025-02-14
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
5
Registration Number
NCT06236815
Locations
🇺🇸

University of Wisconsin, Madison, Wisconsin, United States

Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery

Phase 1
Not yet recruiting
Conditions
PTSD
Post Traumatic Stress Disorder
Interventions
First Posted Date
2024-01-24
Last Posted Date
2024-05-01
Lead Sponsor
Wayne State University
Target Recruit Count
350
Registration Number
NCT06222268
Locations
🇺🇸

WSU MR Research Facility DMC Harper University Hospital, Detroit, Michigan, United States

🇺🇸

Tolan Park Medical Building, Detroit, Michigan, United States

🇺🇸

Wayne State University Eugene Applebaum College of Pharmacy & Health Sciences, Detroit, Michigan, United States

Delta-8-THC vs. Delta-9-THC on Simulated Driving Performance

Phase 1
Recruiting
Conditions
Cannabis
Interventions
First Posted Date
2024-01-23
Last Posted Date
2024-07-31
Lead Sponsor
Johns Hopkins University
Target Recruit Count
45
Registration Number
NCT06218550
Locations
🇺🇸

Johns Hopkins Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States

RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA

Phase 2
Active, not recruiting
Conditions
Obstructive Sleep Apnea
Interventions
Drug: IHL-42X High Dose
Drug: Placebo
Drug: IHL-42X (Optimal Dose)
Drug: IHL-42X Low Dose
First Posted Date
2023-11-24
Last Posted Date
2025-04-20
Lead Sponsor
Incannex Healthcare Ltd
Target Recruit Count
560
Registration Number
NCT06146101
Locations
🇺🇸

Exalt Clinical Research, Chula Vista, California, United States

🇺🇸

CenExel CNS- Los Alamitos, Long Beach, California, United States

🇺🇸

Teradan Clinical Trials, Valrico, Florida, United States

and more 17 locations

Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans

Phase 1
Recruiting
Conditions
Schizophrenia
Cannabis Use Disorder
Interventions
Drug: Placebo
First Posted Date
2023-09-28
Last Posted Date
2025-01-24
Lead Sponsor
Yale University
Target Recruit Count
215
Registration Number
NCT06058702
Locations
🇺🇸

West Haven Veterans Affairs Medical Center, West Haven, Connecticut, United States

Oral Dronabinol-HIV

Phase 1
Recruiting
Conditions
HIV
Interventions
First Posted Date
2023-09-13
Last Posted Date
2024-11-13
Lead Sponsor
Yale University
Target Recruit Count
160
Registration Number
NCT06034314
Locations
🇺🇸

Connecticut Mental Health Center, New Haven, Connecticut, United States

A Feasibility Study of Topical Cannabinoids for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in Adults With Hormone Receptor-Positive Breast Cancer (CanAroma)

Early Phase 1
Completed
Conditions
Musculoskeletal Syndrome
Interventions
Drug: CBD-dominant
First Posted Date
2023-07-07
Last Posted Date
2025-04-04
Lead Sponsor
University of Minnesota
Target Recruit Count
24
Registration Number
NCT05935891
Locations
🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

PK/PD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults

Early Phase 1
Recruiting
Conditions
Pain, Tolerance
Oral vs Vaporized THC
Abuse Liability
Interventions
Drug: 4mg Purified THC in an ethanolic solution
Drug: 2mg Purified THC in an ethanolic solution
Drug: Placebo
First Posted Date
2023-06-18
Last Posted Date
2024-11-08
Lead Sponsor
Yale University
Target Recruit Count
20
Registration Number
NCT05906511
Locations
🇺🇸

VA Connecticut Healthcare System, West Haven, Connecticut, United States

Age-dependent Effects of Smoked and Oral Delta-9-THC

Phase 1
Recruiting
Conditions
Abuse, Drug
Intoxication; Cannabinoids
Pain
Interventions
Drug: Smoked Placebo
Drug: Oral Placebo
First Posted Date
2023-05-18
Last Posted Date
2025-05-06
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
103
Registration Number
NCT05865470
Locations
🇺🇸

UCLA Center for Cannabis and Cannabinoids, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath